Ken Griffin Biogen Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $6.55 Million - $8.14 Million	34,400 Added 27.74%	158,400 $36.7 Million
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $12.6 Million - $15.9 Million	-59,500 Reduced 32.43%	124,000 $26.7 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $25.1 Million - $30.2 Million	-112,800 Reduced 38.07%	183,500 $47.5 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $20.1 Million - $22.7 Million	-79,300 Reduced 21.11%	296,300 $76.2 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $43.8 Million - $50.7 Million	-159,300 Reduced 29.78%	375,600 $107 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $117 Million - $133 Million	-456,400 Reduced 46.04%	534,900 $149 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $84.2 Million - $102 Million	-333,400 Reduced 25.17%	991,300 $275 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $144 Million - $199 Million	740,400 Added 126.72%	1,324,700 $354 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.